Brought to you by the International Journal of Pharmaceutical Compounding FREE TRIAL    FORMULATIONS    MY ACCOUNT 
Compounding This Week Newsletter from
Our Compounding Knowledge, Your Peace of Mind
August 19, 2016  |  Volume 13  |  Issue 33
EXAKT 50EC+ : For the Serious Compounder
Receive a free compounding CD with new subscription to IJPC.
Health Engineering Systems - Mix Consistently, Compound Flawlessly
Loyd V. Allen, Jr., Ph.d., R.Ph Letter from the Editor
U.S. Food and Drug Administration "Import Alerts", Part 1

As we have mentioned in numerous issues of this Newsletter, there are many drug companies in other countries that are sometimes prohibited from sending pharmaceuticals to the U.S. due to quality issues; these may impact the safety of the products and cause patient harm.

An Import Alert informs the FDA field staff and the public that the agency has enough evidence to allow for Detention Without Physical Examination (DWPE) of products that appear to be in violation of FDA laws and regulations. These violations could be related to the product, manufacturer, shipper, and/or other information. DWPE allows the FDA to detain a product without physically examining it at the time of entry.

It should be added, the purposes of the Import Alerts are to:

  • Prevent potentially violative products from being distributed in the U.S.
  • Free-up agency resources to examine other shipments
  • Provide uniform coverage across the country
  • Place the responsibility back on the importer to ensure that the products being imported into the U.S. are in compliance with FDA laws and regulations

Import Alerts can be found on the following websites:

Next week, we will continue this series.

Loyd V. Allen, Jr., PhD, RPh
International Journal of Pharmaceutical Compounding
Remington: The Science and Practice of Pharmacy Twenty-second edition



FDA Catches China's Zhejiang Medicine Hiding Active Pharmaceutical Ingredient Test Data
The FDA has warned another Chinese drugmaker after finding it had been hiding batch test results that showed high peaks of out-of-spec readings. The FDA found that the employees routinely performed "unofficial analyses" that they kept out of the official quality-control records for its APIs. Some of the hidden records "displayed large unknown peaks that were not reported in the official records for the same samples," the FDA reported. And that, the agency said, could mean "the presence of unknown and uncharacterized impurities (including potential contaminants) in your drugs."

European Medicines Agency Nails Artemis India Plant Over Simvastatin Active Pharmaceutical Ingredient Manufacturing Issues
Another API maker in India is in trouble over manufacturing issues; the Artemis Biotech plant in Hyderabad. The German drug authority did the legwork, leading to the recommendation that EU countries not accept the company's simvastatin APIs, plus the possibility its plant certification will be revoked. Among other issues, the authority reported a "demonstrated lack of QA oversight" including keeping important GMP data outside of the quality-management system, problems with data integrity, and conducting the plant's repackaging operations without any documentation and QA approval.


IJPC Now on Facebook and Youtube

Become a fan of the IJPC Facebook page and share ideas, photos, and keep up to date with the latest compounding information -

Learn about the Journal's new multi-media features and view our growing collection of educational and training videos at or by subscribing to our Youtube channel at


Did You Know ...

…that we can all be heroes in our own lives? The following is from Cowboy Ethics—What Wall Street Can Learn from the Code of the West (James P. Owen).


Tip of the Week

"You may feel that the Cowboy's Code does not fit our times, and it is true that few of us will ever be called to test our courage against perils anything like a raging blizzard or a runaway herd of cattle. But we can have the courage to give clients an honest account of bad news, or to confront a business practice that does not put the client first. Every time we make a decision, we can ask ourselves 'Is it right? Is it fair?'. We can decide that our honor and our reputations are not for sale. At a time when heroes are in short supply…



Looking Back

Doesn't kiss you,
Like she useter?
Perhaps she's seen,
A smoother rooster!!
     Burma Shave

Copyright 2016
International Journal of Pharmaceutical Compounding, Inc.
122 N Bryant Ave, Edmond OK 73034
Manage my Email:
Subscribe / Un-Subscribe
Comments or Questions:
Reprints & Permissions: